Trial Profile
LCI-GU-URO-CRI-001: A Phase II Study of Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 25 Apr 2022
Price :
$35
*
At a glance
- Drugs Crizotinib (Primary)
- Indications Bladder cancer; Carcinoma; Urethral cancer; Urogenital cancer
- Focus Therapeutic Use
- 14 Aug 2020 Status changed from active, no longer recruiting to discontinued due to low accrual numbers.
- 22 Nov 2019 Status changed from recruiting to active, no longer recruiting.
- 12 Feb 2019 Planned End Date changed from 1 Dec 2019 to 1 Jan 2023.